Biological activity and stability analyses of knipholone anthrone, a phenyl anthraquinone derivative isolated from Kniphofia foliosa Hochst
Publication date: Available online 31 May 2019Source: Journal of Pharmaceutical and Biomedical AnalysisAuthor(s): Ruth Feilcke, Georgette Arnouk, Boingotlo Raphane, Khumoekae Richard, Ian Tietjen, Kerstin Andrae-Marobela, Frank Erdmann, Susanne Schipper, Katja Becker, Norbert Arnold, Andrej Frolov, Norbert Reiling, Peter Imming, Serge A.T. FobofouAbstractKnipholone (1) and knipholone anthrone (2), isolated from the Ethiopian medicinal plant Kniphofia foliosa Hochst. are two phenyl anthraquinone derivatives, a compound class known for biological activity. In the present study, we describe the activity of both 1 and 2 in several biological assays including cytotoxicity against four human cell lines (Jurkat, HEK293, SH-SY5Y and HT-29), antiplasmodial activity against Plasmodium falciparum 3D7 strain, anthelmintic activity against the model organism Caenorhabditis elegans, antibacterial activity against Aliivibrio fischeri and Mycobacterium tuberculosis and anti-HIV-1 activity in peripheral blood mononuclear cells (PBMCs) infected with HIV-1c. In parallel, we investigated the stability of knipholone (2) in solution and in culture media. Compound 1 displays strong cytotoxicity against Jurkat, HEK293 and SH-SY5Y cells with growth inhibition ranging from approximately 62-95% when added to cells at 50 µM, whereas KA (2) exhibits weak to strong activity with 26, 48 and 70% inhibition of cell growth, respectively. Both 1 and 2 possess significant antiplasmodial activity against P...
Authors: Kim DJ, Jeong S, Kong SG, Lee HS PMID: 31309096 [PubMed]
ConclusionWe describe one of the largest cohorts of consecutive uveitis patients referred to a department of internal medicine. The high percentage of uveitis associated with underlying (systemic) diseases highlights the need for a multidisciplinary approach, in order to reduce the diagnostic delay.
Authors: Schloßhauer T, Priepke E, Rehart S, Kuehn S, Jahn-Muehl B, Rieger UM Abstract Tuberculosis is a central global health problem with an incidence of 10 million new cases per year and more than one million deaths per year. Contrary to this, osseous tuberculosis represents an extremely rare entity of tuberculosis. Osseous tuberculosis is challenging beginning with the correct diagnosis, adequate surgical as well infectiological treatment as well as extremity reconstruction. Facing increased migration and therefore increasing numbers of cases of tuberculosis in western countries, the question of a reliabl...
We reported the case of a 45-year-old male, HIV positive, naïve to antiretroviral treatment, admitted to the Department of Medicine of the Central Hospital of Beira to investigate chronic enlargement of the testicles. PMID: 31305938 [PubMed - as supplied by publisher]
Publication date: Available online 16 July 2019Source: Urology Case ReportsAuthor(s): W.M. Borges, G.R. Bechara, M.M.L. de Miranda, G.B. de Figueiredo, B.A. Venturini, C.R. LaghiAbstractTuberculosis (TB) is a secular disease caused by a bacillus, highly prevalent in Brazil. The genito-urinary tract involvement is rare, with the epididymis the most affected location. Treatment usually involves the combination of 3 to 4 drugs for TB for 6 months and surgery can be useful in complications.
Publication date: Available online 15 July 2019Source: Respiratory Medicine Case ReportsAuthor(s): Yanqiu Wei, Peng Chen, Huihui Yue, Gaohong Sheng, Jiaojiao Chu, Hui-Lan ZhangAbstractGiant cell interstitial pneumonia (GIP) is an exceedingly rare lung disease, usually due to occupational exposure to hard-metal compounds (tungsten, carbide, cobalt). Diagnosis of GIP is mainly based on the presence of multinucleated giant cell (MNGC) in alveolar spaces by histologic examination. Here, we present a case of GIP with multi-organ involvement. A 63-year-old man was diagnosed with tuberculosis firstly, but conventional treatment d...
Condition: Tuberculosis, Meningeal Interventions: Drug: LZD; Drug: High dose RIF; Drug: Standard dose RIF Sponsors: University of California, San Francisco; MRC/UVRI Uganda Research Unit on Aids; London School of Hygiene and Tropical Medicine Not yet recruiting
No abstract available
No abstract available
[Vanguard] Nigeria recorded a funding gap of $310.84 million or N111.9 billion for Tuberculosis, TB, control in 2018.